Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (ISRCTN56831337) titled 'Impact of a probiotic supplement on menopause' on Aug. 12.
Study Type: Interventional
Study Design:
Single-arm virtual real-world evidence pilot study (Quality of life, Treatment, Safety, Efficacy)
Primary Sponsor: Symprove Ltd
Condition:
Menopause
Other
Intervention:
All participants will receive a 12-week course of Symprove to take 70ml once a day. Symprove is a gut supplement that contains billions of live and active bacteria.
Recruitment Status: Recruiting
Phase: Not Applicable
Date of First Enrollment: 11/08/2025
Target Sample Size: 100
Countries of Recruitment:
England
United Kingdom
To know...